Pleasure for Food and Endocannabinoids in Obesity

NCT ID: NCT01985139

Last Updated: 2025-01-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2019-11-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Disturbances in hedonic and motivational processes play a major role in the pathophysiology of obesity. To date, experimental approaches for the study of emotional and motivational processing rely on subjective assessment scales. We have therefore developed two novel computer-generated tasks challenging respectively visual and temporal discrimination capacities for a quantitative and objective measurement of the hedonic and motivational state in humans. According to the task, the subjects are asked to view and to compare two stimuli, an appetitive one (food pictures) and its devalued counterpart (food pictures in greyscale), at each trial, assessing either the size (task A) or the duration of presentation (task B). From these considerations, the present project aims at using our novel tool to: i) assess the hedonic and motivational state in subjects with obesity, ii) compare their responses with healthy volunteers, and iii) establish relationships with biological markers known to be highly involved in the regulation of both emotional and motivational processes, such as endocannabinoids. The present project should demonstrate that the behavioral tests validated in our laboratory are relevant experimental tools for the diagnostic/clinical assessment and for the phenotypic characterization of obese patients. The application of the test in the therapeutic context could add further information about the efficacy and relevance of the chosen therapy. Finally, our project will provide information on the biological substrates of hedonic and motivational impairments that might become target of therapy in obesity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Disturbances in hedonic and motivational processes play a major role in the pathophysiology of reward-related diseases, such as obesity. To date, experimental approaches for the study of emotional and motivational processing rely on subjective assessment scales. We have therefore developed and validated a novel computer-generated test challenging visual and temporal discrimination capacities in humans. The subjects are asked to view and to compare two stimuli, an appetitive one (food pictures; F) and its devalued counterpart (food pictures in greyscale; D), at each trial, assessing either the size (task A) or the duration of presentation (task B). Geometric figures are used as controls and presented in color (C) or greyscale (D). Both tasks are registered under the French agency for the protection of computer software. Here, we propose to use our novel test to: i) assess the hedonic and motivational state in subjects suffering from obesity, ii) compare their responses with healthy volunteers, and iii) establish relationships with biological markers known to be highly involved in the regulation of both emotional and motivational processes, such as endocannabinoids. Responses to the test in obese patients will be evaluated during two separate experimental sessions under either fasting or satiety conditions.

The present study is expected to begin mid-November 2013 for a total duration of 24 consecutive months. A sample of 25 patients suffering from obesity will be recruited and compared with 25 healthy normal volunteers who are free from any previous or current metabolic and psychiatric disorders. They will be matched on age and sex. They will be screened using the "Association pour la Méthodologie et la Documentation en Psychiatrie" questionnaire for obtaining a series of information, comprising the marital status, number of children, number of siblings, education and training, professional qualifications, significant life events… They will be evaluated with the Mini-International Neuropsychiatric Interview in order to determine the presence of mood disorders and associated psychopathology. The Three-Factor Eating Questionnaire will be employed for measuring three separate aspects of eating behavior: cognitive restraint, uncontrolled eating, and emotional eating. This will be completed with the Multidimensional Body Self-Relations Questionnaire and the State-Trait Anxiety Inventory in order to assess the body satisfaction and anxiety levels, respectively. Beyond all these assessments, two separate experimental sessions will be conducted, one in satiety and the other in fasting. During each session, the participants will be asked to perform the two validated instrumental tasks in front the screen of a computer. Plasma levels of endocannabinoids will be monitered by collecting blood samples prior to the consumption of a calorically-defined meal and while carrying out the computer-generated tasks under satiety. Blood will be withdrawn at the same time-points during the session in fasting. Visual analogue scales (VAS) assessing hunger levels will be completed before blood is collected. A VAS will be also used for the global assessment of appetitive properties of the viewed food images just before the end of the second experimental session.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Obese patients

Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels

Group Type EXPERIMENTAL

Computer-based tasks

Intervention Type BEHAVIORAL

Computer-based tasks designed to assess size and time discrimination capacities

Blood sampling

Intervention Type BIOLOGICAL

Blood drawn for the measurement of circulating endocannabinoids concentrations

Normal-weight healthy volunteers

Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels

Group Type EXPERIMENTAL

Computer-based tasks

Intervention Type BEHAVIORAL

Computer-based tasks designed to assess size and time discrimination capacities

Blood sampling

Intervention Type BIOLOGICAL

Blood drawn for the measurement of circulating endocannabinoids concentrations

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Computer-based tasks

Computer-based tasks designed to assess size and time discrimination capacities

Intervention Type BEHAVIORAL

Blood sampling

Blood drawn for the measurement of circulating endocannabinoids concentrations

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Obese patients :

1. Be between 18 and 60 year-old
2. Have a body mass index ranging from 35 to 50 kg/m2
3. Have no previous history of surgical treatment of obesity
4. Have received no standard intervention for obesity within the last 3 months before study
5. Have a stable weight (variation \<5%) within the last 3 months before study
6. Have a restriction score \<9 on the three-factor eating questionnaire
7. Be free from any current and previous psychiatric disorder, such as major depression or drug abuse/dependence
8. Understand and accept the design and constraints of the present study
9. Be a beneficiary or member of health insurance plan
10. Provide written consent to the study after receiving clear information

Healthy volunteers :

1. Be between 18 and 60 year-old
2. Be free from any current and previous psychiatric disorder, such as major depression or drug abuse/dependence
3. Understand and accept the design and constraints of the present study
4. Be a beneficiary or member of health insurance plan
5. Provide written consent to the study after receiving clear information

Exclusion Criteria

Obese patients :

1. Suffer from monogenic obesity
2. Take any psychotropic treatment such as anxiolytic/hypnotic drugs over the last week preceding the study
3. Be a pregnant or nursing woman
4. Use alcohol over the last two days preceding the study

Healthy volunteers :

1. Suffer from any current and previous somatic or psychiatric condition
2. Have a body mass index below 18,5 kg/m2 or above 25 kg/m2
3. Take any psychotropic treatment such as anxiolytic/hypnotic drugs over the last week preceding the study
4. Be a pregnant or nursing woman
5. Use alcohol over the last two days preceding the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bruno Aouizerate, Professor

Role: PRINCIPAL_INVESTIGATOR

Neurocentre Magendie (INSERM U862)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Neurocentre Magendie (INSERM U862)

Bordeaux, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-A00982-43

Identifier Type: REGISTRY

Identifier Source: secondary_id

C13-33

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Decision-making and Food Intake
NCT07133529 RECRUITING NA
Liking of Snack Foods - Sub-Study 1
NCT00200213 COMPLETED NA
Energy Turnover and Appetite
NCT05365685 COMPLETED NA